<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ N4P.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #ef4444 0%, #dc2626 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">N4P.L</div>
            <div class="company-name">N4 Pharma Plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£3,953,331</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 1229 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ AVOID</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">34</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">15</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fee2e2; color: #991b1b;">BROKEN</span>
            </div>
            
            <div class="thesis-line">
                AVOID - BROKEN timing with 34/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üè≠</span>
                CrashDash Intelligence ‚Ä¢ Industrials
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#f59e0b 237.6deg, #e5e7eb 237.6deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #f59e0b;">66</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #f59e0b; margin-bottom: 12px;">HIGH PANIC</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü† Fear dominant - watch for reversal signs</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 40/40</div>
                            <div>üìâ Volume: 10/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 10/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #f59e0b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üü† Fear 66/100</span><span style="display: inline-block; background: #ef4444; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">‚ùå Broken</span><span style="display: inline-block; background: #64748b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">‚ùì Conf 15</span>
                </div>
                
                <!-- Opportunity Flag -->
                
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 64.8deg, #e5e7eb 64.8deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">18</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">‚ö™ LOW COMPRESSION (Early/Weak)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.7</strong> signals/week</div>
                                <div><strong>0</strong> RSI &lt; 20 events</div>
                                <div><strong>0</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+118%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">8/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 20.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.7 signals/week | üéØ MILD COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Normal volume</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 33.33333333333333%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Baseline mover (118%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 40/40 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üìà Historical upside: 118% proven capacity</div><div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üí∞ Deep value: 73% off recent peak</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    ‚úÖ Facts align with low fear - Normal risk/reward
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Industrials)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book decline or cancellations</div><div>‚Ä¢ Margin compression (input costs)</div><div>‚Ä¢ Cyclical demand weakness</div>
                    </div>
                    <div style="margin-top: 12px; padding: 10px; background: #fef3c7; border-radius: 8px; font-size: 12px; color: #92400e; font-weight: 600;">üö® Active: Project delays or overruns</div>
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book growth or new contracts</div><div>‚Ä¢ Margin recovery (efficiency gains)</div><div>‚Ä¢ Cyclical upturn (capex recovery)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Director Appointment</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Holding(s) in Company</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Directorate Change</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Directorate Changes</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Placing and Subscription to raise ¬£630,000</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #f59e0b;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #f59e0b; font-size: 20px;">AVOID</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚ùå AVOID - timing BROKEN
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (2/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üî¥</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">66/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ùå</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">BROKEN</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">34/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ùì</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">15/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üè≠</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">1 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 34/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: BROKEN</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 2 rallies, 118% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 15/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 8/20 ‚Ä¢ Score: 10/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 82.6% from peak ‚Ä¢ Score: 17/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Above average volume</strong><br><small>1.7x average ‚Ä¢ Score: 6/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>2 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Good upside</strong><br><small>Historical best: +118% ‚Ä¢ Score: 8/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">-73%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">118%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">-0.6x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Deep drawdown - thesis failing</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">current return=-72.7% ‚Ä¢ timing=BROKEN</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Round-trip collapse - pump and dump pattern</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True ‚Ä¢ current return=-72.7%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2022-09-05</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Avoid</div>
                    <div style="font-size: 14px; opacity: 0.9;">Do not trade - thesis invalidated</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0%</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">N/A</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">N/A</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows BROKEN timing with 34/100 APEX score. Historical data shows 2 rallies averaging 118% upside. Current position: -72.7%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Limited upside case without catalysts</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Deep drawdown (-72.7%) suggests broken thesis</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Thesis invalidated. Avoid or exit.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 15/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #ef4444 0%, #ef4444dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #ef444440;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #ef4444 0%, #ef4444dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìâ</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Director Appointment</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">DIRECTOR SELL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Negative signal - caution warranted on near-term positions.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9th Sep 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #ef4444;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #ef4444;">BEARISH</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Amorsa Therapeutics</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
9 Sep 2024 07:00
RNS Number : 2998D
N4 Pharma PLC
09 September 2024
9 September 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Director Appointment
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec¬Æ, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce the appointment of Dr Michael Palfreyman as an independent Non-Executive Director of the Company with immediate effect.
Dr Palfreyman has more than four decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK) and has co-founded and developed several biotechnology companies including, among others, Co-Founder of
Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for US$230 million and Co-Founder and CSO of Amorsa Therapeutics, Inc. developing novel treatments for depression and pain where he oversaw a successful US$180 million exit
.
Dr Palfreyman currently advises Cybin Inc. listed on the New York Exchange (NYSE: CYBN) and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc. Dr Palfreyman has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals.
Dr Palfreyman
is an Emeritus Fellow of the American College of Neuropsychopharmacology. He is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters.
Dr Palfreyman joins the Company's remuneration and audit committees.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are delighted to welcome someone of Mike's calibre to the board of N4 Pharma. His successful career in drug discovery and development is sure to be a great asset to the Company, as will his industry connections and contacts across the US which we are confident will help in our drive to commercialise Nuvec.¬Æ"
Mike Palfreyman, commented:
"A
s a scientist and entrepreneur who works at the cutting edge of therapeutic development, N4 Pharma's unique delivery technologies clearly show the potential to advance the clinical applications of several promising therapeutics, and I am excited by the opportunity to join the board of this exceptional company."
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Dr Michael Gavin Palfreyman, aged 78 :
Current Directorships/Partnerships
Past Directorships/Partnerships (within 5 years)
Palfreyman BioPharm Advisors, LLC
AlNivo Therapeutics, Inc.
Adelia Therapeutics, Inc.
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To find out more, visit
Via N4 Pharma Investor Hub
Sign up at
investors.n4pharma.com
https://investors.n4pharma.com/link/lejRpe
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44(0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44(0)20 3657 0050
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec¬Æ and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec¬Æ or Liptide¬Æ as the delivery vehicle for these products. As these products progress through pre‚Äêclinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit
www.n4pharma.com
or sign up at
investors.n4pharma.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
BOAFLFESASIRIIS
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üèõÔ∏è</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Holding(s) in Company</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">HOLDINGS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Major holder disclosure - routine regulatory filing.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">9th May 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">8:24 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Road Town</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
9 May 2025 08:24
RNS Number : 0549I
N4 Pharma PLC
09 May 2025
TR-1: S
tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
(to be sent to the relevant issuer
and
to the FCA in Microsoft Word format if possible)
i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached
ii
:
N4 Pharma Plc
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
UK
2. Reason for the notification
(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Dematerialisation of holding into Fiske Nominees Limited
x
3. Details of person subject to the notification obligation
iv
Name
Tracarta Limited
City and country of registered office (if applicable)
OMC Chambers, Wickhams Cay 1, Road Town, Tortola, British Virgin Islands
4. Full name of shareholder(s)
(if different from 3.)
v
Name
Fiske Nominees Limited
City and country of registered office (if applicable)
100 Wood Street, London, England, EC2V 7AN
5. Date on which the threshold was crossed or reached
vi
:
01/05/2025
6.
Date on which issuer notified (DD/MM/YYYY):
08/05/2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of
voting rights through
financial instruments(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B)
vii
Resulting situation on the date on which threshold was crossed or reached
18.02
-
18.02
150,000,000
Position of previous notification (if
applicable)
18.02
-
18.02
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
viii
A: Voting rights attached to shares
Class/type ofshares
ISIN code (if possible)
Number of voting rights
ix
% of voting rights
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
GB00BYW8QM32
150,000,000
-
18.02
-
SUBTOTAL 8. A
150,000,000
18.02
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Physical or cash
Settlement
xii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
xiii
Full
chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)
xiv
X
Name
xv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Tracarta Limited
18.02
-
18.02
10.
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
xvi
Place of completion
St. Peter Port, Guernsey
Date of completion
08/05/2025
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
HOLFIFFDEVIAIIE
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #f59e0b 0%, #f59e0bdd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #f59e0b40;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #f59e0b 0%, #f59e0bdd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üîÑ</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Directorate Change</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">CHANGE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Organizational change - assess impact on operations and strategy.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">8th Jul 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #f59e0b;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #f59e0b;">CAUTION</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Per Schedule</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">49%, 51%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
8 Jul 2025 07:00
RNS Number : 0438Q
N4 Pharma PLC
08 July 2025
8 July 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Directorate Change
N4 Pharma plc (AIM: N4P),
the UK biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases
, is pleased to announce the appointment of Edward Wardle
as a Non-Executive Director of the Company with immediate effect.
Edward is joining the Board as a representative of Northern Standard Limited, which is the Company's largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development. Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a Senior Business Development Executive at Ironveld plc. He joined the Board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a Non-Executive Director in May 2025.
Nigel Theobald, Chief Executive Officer of N4 Pharma, said:
"We are delighted to welcome Ed to the Board of N4 Pharma, representing our largest shareholder. His experience in strategy, corporate governance, business development, and his background in innovative technologies will be invaluable as N4 Pharma develops its Nuvec¬Æ platform and continues to build out its data packages to secure licensing opportunities."
Edward Wardle commented:
"
Northern Standard sees a future where N4 Pharma's Nuvec¬Æ platform shifts the paradigm of drug delivery by enabling the evolution of advanced RNA therapies; where time-consuming, in-clinic injections become something as small as a pill. We believe N4 Pharma has the technology, IP, and world-class team necessary to deliver this future, and are honoured to support them as they do.
"
- Ends -
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Edward James Norman Wardle, aged 34:
Current Directorships/Partnerships
TheraCryf¬†PLC
The Hammer Organization Limited
Otherworld Piccadilly Limited
The Dream Corporation Limited*
Otherworld Dublin Limited
Past Directorships/Partnerships (within 5 years)
Otherworld Manchester Limited
Otherworld Birmingham Limited
*Per Schedule Two paragraph (g)(v) of the AIM Rules for Companies - The Dream Corporation Limited is currently undergoing creditors' voluntary liquidation, with KRE Corporate Recovery appointed as licensed insolvency practitioners on 22 July 2024. It is currently anticipated there will not be surplus funds to pay a distribution to any class of creditor.
Edward Wardle is a 49% shareholder in Northern Standard Limited, which is interested in 150,000,000 ordinary shares in the Company. Northern Standard Limited is a 51% owned subsidiary of Tracarta Limited, a company in which John Wardle, Edward Wardle's father, has a beneficial interest.
In addition, Mr Wardle personally holds 18,750,000 warrants to subscribe for new ordinary shares in the Company exercisable at 0.4p per share which expire on 4 April 2030.
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:
investors.n4pharma.com
https://investors.n4pharma.com/link/0rJNYr
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,
protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
BOAUBVSRVBUBRAR
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #f59e0b 0%, #f59e0bdd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #f59e0b40;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #f59e0b 0%, #f59e0bdd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üîÑ</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Directorate Changes</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">CHANGE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Organizational change - assess impact on operations and strategy.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">8th Jan 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #f59e0b;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #f59e0b;">CAUTION</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Avacta Life</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">3.9%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
8 Jan 2025 07:00
RNS Number : 4808S
N4 Pharma PLC
08 January 2025
8 January 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Directorate Changes
N4 Pharma plc (AIM: N4P),
the biotech developing Nuvec¬Æ, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases
, is pleased to announce the appointment of Dr Alastair Smith as an independent Non-Executive Director of the Company with immediate effect.
In addition, David Templeton has retired as a Director of the Company with immediate effect due to personal reasons.
Alastair was the founder and former Chief Executive Officer of Avacta Group plc ("Avacta"), an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006.
Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company advancing its proprietary pre|CISIONTM tumour targeting platform
[1]
and a diagnostics business executing an M&A-led growth strategy in Europe focused on healthcare professionals.
Alastair joins the Company's remuneration and audit committees.
As part of his remuneration package, Alastair has been granted options over 5 million ordinary shares in the Company at an exercise price of 0.75p per share. The options vest in three equal tranches on the first, second and third anniversaries from the date of grant. The options have a term of ten years from the date of grant.
Nigel Theobald, Chief Executive Officer, N4 Pharma, commented:
"We are delighted to welcome Alastair to the Board of N4 Pharma. His experience in having founded and grown a start-up to become one of the UK's leading life science businesses will be invaluable in supporting the commercialisation of Nuvec¬Æ and advancing our pipeline of innovative therapies.
"On behalf of my fellow Directors and everyone involved with N4 Pharma, I would like to thank David for all he has contributed over his years with the Company. Whilst he will be sorely missed, his work on dual loading of
Nuvec¬Æ
and its potential for oral delivery has left us with a true point of difference and a clear path towards Phase 1 clinical trials. We wish him all the best for the future."
Alastair Smith commented:
"I am delighted to be joining the Board of N4 Pharma. I see strong parallels between N4 Pharma and Avacta; both building a pipeline of therapies that are strongly differentiated by a proprietary platform technology and offer additional opportunities for early commercialisation through licensing.
"N4 Pharma's Nuvec¬Æ platform has the potential to solve a critical issue in the gene therapy market, a delivery system that can target multiple nucleic acids to specific tissues, and with the potential for oral delivery. This is hugely valuable and has the potential to make Nuvec¬Æ the delivery platform of choice for the gene therapy industry.
"I believe that Nuvec¬Æ will allow the Company to build a differentiated drug pipeline to drive long-term value and generate commercial progress through platform licensing deals and partnerships in the near term."
The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Dr David Alastair Maclaughlin Smith, aged 58:
Current Directorships/Partnerships
Past Directorships/Partnerships (within 5 years)
Sparta BioDiscovery Limited
Avacta Group plc
Avacta Animal Health Ltd
Avacta Animal Health Inc.
Avacta Analytical Limited
Affimer Limited
Avacta Ltd
Avacta Life Sciences Limited
Avacta Life Sciences Inc.
Avacta Group Trustee Limited
Avacta Finance (Jersey) Limited
AffyXell Therapeutics
Crossco (1127) Limited
Launch Diagnostics Holdings Limited
Launch Diagnostics Ltd
Coris BioConcept SrL
Coris Holdings SrL
[1]
Avacta's lead clinical programme, AVA6000, based on the Company's proprietary tumour targeting platform pre|CISION‚Ñ¢, is a modified form of the established chemotherapy doxorubicin. pre|CISION‚Ñ¢ is designed to release the active chemotherapy only in the tumour tissue, thereby sparing healthy tissue and improving the safety and tolerability of this effective anti-cancer therapy. AVA6000 is in the late stage of Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours and has been shown to dramatically reduce the severity and frequency of doxorubicin toxicities.
For more information please contact:
N4 Pharma plc
Nigel Theobald, Chief Executive Officer
Luke Cairns, Executive Director
Investor questions on this announcement
We encourage all investors to share questions
on this announcement via our investor hub
Via N4 Pharma Investor Hub
Sign up at
investors.n4pharma.com
https://investors.n4pharma.com/link/VyEJpe
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0) 20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker/James Pope
Tel: +44 (0) 20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0) 113 730 3896
About N4 Pharma
N4 Pharma is a biotech company developing Nuvec¬Æ, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases
.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec¬Æ has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,
protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec¬Æ platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec¬Æ platform.
With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.
For further information on the Company visit
www.n4pharma.com
or sign up at
https://investors.n4pharma.com/auth/signup
.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Alastair Smith
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
N4 Pharma plc
b)
LEI
213800I841D2RKMFK955
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
b)
Nature of the transaction
Issue of options over ordinary shares of 0.4p each
c)
Price(s) and volume(s)
Price(s)
Volume(s)
0.75p exercise price
5,000,000
d)
Aggregated information
- Aggregated volume
- Price
n/a
e)
Date of the transaction
8 January 2025
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
BOAPKOBNFBKDODK
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Placing and Subscription to raise ¬£630,000</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7th Jun 2024</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">10:18 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Placing Share</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
7 Jun 2024 10:18
RNS Number : 6293R
N4 Pharma PLC
07 June 2024
7 June 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Placing and Subscription to raise ¬£630,000
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec¬Æ, a novel delivery system for cancer treatments and vaccines,
is pleased to announce that it has raised a total of ¬£630,000 (before expenses) through a placing of 118,000,000 new ordinary shares of 0.4pence each in the Company (the "Placing Shares"), and a subscription of 8,000,000 new ordinary shares of 0.4pence each (the "Subscription Shares"), at an issue price of 0.5p (the "Issue Price") per Placing Share and Subscription Share (together, the "Fundraise").
The net proceeds of the Fundraise will be used to advance its three primary work streams whilst also providing working capital into 2025. Specifically:
‚óè
Based on the encouraging data obtained on the use of Nuvec¬Æ for multiple delivery of siRNA and its oral work, the Company will commence work with the University of Queensland for the proof of concept for a product to treat irritable bowel disease ("IBD"). The program will seek to demonstrate through
in vitro
and
in vivo
studies that dual loaded Nuvec¬Æ in an oral capsule can reduce inflammation associated with IBD
‚óè
Subject to data from the ongoing work with SRI International Inc ("SRI"), continue to support further development work with SRI's MGS technology whilst supporting the co-marketing of any resulting data to collaborators and commercial partners
‚óè
The increased funds will provide flexibility to further support Nanogenics in obtaining pre-IND Approval for ECP105 whilst
in vivo
work concludes and it awaits the result of its application for orphan designation status for ECP105 which, if granted, would potentially give seven years exclusivity in the USA on the product post authorisation
‚óè
In addition to the core work streams outlined above, all of which are expected to provide steady newsflow for the rest of the year, work will continue in the background to identify a distribution partner to supply Nuvec¬Æ to Adeno-Associated virus ("AAV") vector companies
‚óè
The Board will also look to potentially add additional director(s) with proven track records or contacts in the commercialisation and/or sale of products and IP in the pharmaceutical and biotech space
Nigel Theobald, Chief Executive Officer of the Company, has added an explanatory video to the N4 Pharma investor hub which can be found here:
https://investors.n4pharma.com/link/XyMJ5e
.
Please submit any questions you may have and the management team will endeavour to respond as soon as possible.
A comment from Nigel Theobald:
"
We are pleased to have raised these funds in difficult market conditions for small caps. The money will underpin our work efforts whilst we look to move through key milestones and, we believe, value inflexion points, across our three main work streams during the rest of the year. In doing so, we hope to be able to co-market our combined technologies with SRI, complete a proof of concept for an oral IBD product and achieve orphan designation and pre IND approval for Nanogenics' ECP105. All the while this work will be widening and strengthening our IP position across the Company.
"
Broker Warrants
As part of its fee, Turner Pope Investments (TPI) Limited, will be issued with warrants ("Broker Warrants") to subscribe for 7,560,000 new ordinary shares exercisable at the Issue Price. The Broker Warrants have a term of 36 months from the date of admission of the Placing Shares and Subscription Shares to trading on AIM and are being issued under the Company's existing share authorities.
Application for Admission
The Fundraise has been conducted utilising the Company's existing share authorities. Application has been made for the Placing Shares and Subscription Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and that dealings will commence at 8.00 a.m. on or around 13 June 2024. Once issued, the Placing Shares and Subscription Shares will rank
pari passu
with the Company's existing ordinary shares.
Total Voting Rights
Following Admission, the enlarged issued share capital of the Company will comprise 394,780,349 ordinary shares of 0.4 pence each ("Ordinary Shares"). The Company does not hold any Ordinary Shares in treasury. Consequently, 394,780,349 is the figure which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
For more information please contact:
N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
Via N4 Pharma Investor Hub
Sign up at
investors.n4pharma.com
SP Angel Corporate
Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44(0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44(0)20 3657 0050
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec¬Æ.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec¬Æ as the delivery vehicle for these antigens. As these products progress through pre‚Äêclinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit
www.n4pharma.com
or sign up at
investors.n4pharma.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
IOEKDLBBZQLFBBQ
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-17 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>